Maximizing IP Value: Strategize Now to Win Later
As part of Goodwin’s exclusive programming during the BIO International Convention in Boston, we invite you to join us for a focused discussion on how biotech and pharma companies can protect and maximize the value of their intellectual property. In a time when innovation is critical and IP disputes are on the rise, getting ahead of IP strategy is more important than ever.
Through a candid conversation with leading litigators and experts, we’ll examine real-world disputes, lessons learned, and practical strategies to preserve competitive edge and prepare for what’s ahead.
Please RSVP here and see below for more details!
Date & Time: Wednesday, June 18 from 10:00 AM – 11:30 AM ET
Location: Goodwin’s Boston Office, 100 Northern Avenue, Boston, MA 02210
10:00 – 10:30 PM | Registration
10:30 PM – 11:30 PM | Unlocking the Long-Term Value of Your IP – Lessons from the Trenches
-
- Elaine Blais, Partner, Goodwin
- Robert Frederickson, Partner, Goodwin
- Emily Rapalino, Partner, Goodwin
- Daryl Wiesen, Partner, Goodwin
- Leda Trivinos, Senior Partner, Intellectual Property, Flagship Pioneering
For the first time in decades, the Supreme Court will consider patent law’s “enablement” requirement, in Amgen Inc. v. Sanofi. That requirement is often a key point in litigation when a patent claims a class of novel compounds or antibodies. In the oral argument on March 27, the Supreme Court will examine the Federal Circuit’s holding that patentees must disclose enough information to “enable” people of ordinary skill in the relevant art to “reach the full scope” of the claimed invention. In this day-after webinar, litigators from Goodwin’s Supreme Court and IP Litigation practices will recap the argument and explain what it could mean for the future of the enablement requirement.